These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9441094)

  • 21. Tuberculosis in the elderly in Hong Kong.
    Chan-Yeung M; Noertjojo K; Tan J; Chan SL; Tam CM
    Int J Tuberc Lung Dis; 2002 Sep; 6(9):771-9. PubMed ID: 12234132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex differences in tuberculosis in Hong Kong.
    Chan-Yeung M; Noertjojo K; Chan SL; Tam CM
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):11-8. PubMed ID: 11931395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
    Savic RM; Lu Y; Bliven-Sizemore E; Weiner M; Nuermberger E; Burman W; Dorman SE; Dooley KE
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3035-42. PubMed ID: 24614383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
    Langdon G; Wilkins JJ; Smith PJ; McIlleron H
    Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
    Ena J; Valls V
    Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2001 Sep; 5(9):815-23. PubMed ID: 11573892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of individual drugs in the chemotherapy of tuberculosis.
    Mitchison DA
    Int J Tuberc Lung Dis; 2000 Sep; 4(9):796-806. PubMed ID: 10985648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for multidrug-resistant tuberculosis in Hong Kong.
    Law WS; Yew WW; Chiu Leung C; Kam KM; Tam CM; Chan CK; Leung CC
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1065-70. PubMed ID: 18713506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis.
    Peloquin CA; Maslow JN; Mikota SK; Forrest A; Dunker F; Isaza R; Peddie LR; Peddie J; Zhu M
    J Vet Pharmacol Ther; 2006 Dec; 29(6):581-5. PubMed ID: 17083464
    [No Abstract]   [Full Text] [Related]  

  • 35. Activity of rifapentine against Mycobacterium avium infection in beige mice.
    Klemens SP; Cynamon MH
    J Antimicrob Chemother; 1992 May; 29(5):555-61. PubMed ID: 1624393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
    Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
    Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys.
    Emary WB; Toren PC; Mathews B; Huh K
    Drug Metab Dispos; 1998 Aug; 26(8):725-31. PubMed ID: 9698285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
    Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
    J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.